Johnson & Johnson (JNJ) has submitted a new application to the U.S. FDA to expand the use of Stelara (ustekinumab) for treating children aged two and older with moderate to severe ulcerative colitis.

For the third straight quarter, AbbVie has jacked up its revenue forecast for 2025. The Illinois drugmaker has raised its guidance by $400 million, now expecting sales to reach $60.9 billion. | ...

The new approval allows patients to transition to a single 200mg subcutaneous injection once every 4 weeks, following completion of the induction phase.

In patients with inflammatory bowel disease, severe gastrointestinal infections may trigger disease flares, requiring ...

The McGill IBD Research Group, in partnership with the Montreal General Hospital Foundation, will hold its annual fundraising ...

Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ...